Sergey Yurasov
Chief Tech/Sci/R&D Officer bij BLACK DIAMOND THERAPEUTICS, INC.
Actieve functies van Sergey Yurasov
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-06-2022 | - |
Loopbaan van Sergey Yurasov
Eerdere bekende functies van Sergey Yurasov
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NUVATION BIO INC. | Chief Tech/Sci/R&D Officer | 01-09-2019 | 01-02-2022 |
IMMUNE DESIGN CORP | Chief Tech/Sci/R&D Officer | 04-10-2016 | 02-04-2019 |
The Rockefeller University | Corporate Officer/Principal | - | - |
Hoffman-La Roche, Inc. | Corporate Officer/Principal | - | - |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - | - |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
Opleiding van Sergey Yurasov
Russian State Medical University | Doctorate Degree |
Research Institute for Pediatric Oncology | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Rusland | 3 |
Operationeel
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 2 |
Sectoraal
Health Technology | 7 |
Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
NUVATION BIO INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Hoffman-La Roche, Inc. | Health Technology |
- Beurs
- Insiders
- Sergey Yurasov
- Ervaring